Stock Events

Stock Events

Affymax 

$0.001000
6
-$0.00-9.09% Monday 13:30

Statistics

Day High
0.001
Day Low
0.001
52W High
0.003
52W Low
0.0001
Volume
115
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Dec 14
$0.05
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
0

Financials

-1,053.62%Profit Margin
Unprofitable
2012
2013
1.37MRevenue
-14.42MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AFFY. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap191.7B
Amgen is a biotechnology firm that competes with Affymax in the development of therapies for anemia, particularly in patients with chronic kidney disease, similar to Affymax's peginesatide.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in various therapeutic areas including anemia management, making it a competitor to Affymax.
Roche
RHHBY
Mkt Cap332.67B
Roche, with its strong portfolio in anemia and kidney disease treatments, competes directly with Affymax's anemia products.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca operates in similar therapeutic areas as Affymax, including treatments for anemia associated with chronic kidney disease.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline competes with Affymax in the development and marketing of medications for anemia and other conditions related to chronic kidney disease.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie competes in the area of chronic kidney disease treatments, offering products that could be used as alternatives to Affymax's offerings.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is involved in the research and development of drugs for various conditions, including anemia, making it a competitor to Affymax.
Novartis
NVS
Mkt Cap292.07B
Novartis has a broad portfolio that includes treatments for chronic kidney disease and anemia, positioning it as a competitor to Affymax.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb has a presence in the anemia treatment market, particularly for patients with kidney disease, competing with Affymax.
Sanofi
SNY
Mkt Cap105.92B
Sanofi develops and markets drugs for a wide range of conditions, including anemia, making it a competitor to Affymax in this therapeutic area.

About

Affymax, Inc. presently lacks any substantial operational activities. In its earlier history, the firm concentrated on the creation of pharmaceutical agents designed to improve therapies for severe and frequently fatal health issues across the United States. Established in 2001, its corporate base is situated in New York, New York.
Show more...
CEO
Mr. Mark G. Thompson
Employees
2
Country
United States
ISIN
US00826A1097

Listings

OTC Link
US
AFFY

0 Comments

Share your thoughts

FAQ

What is Affymax stock price today?▼
The current price of AFFY is $0.00 USD — it has decreased by -9.09% in the past 24 hours. Watch Affymax stock price performance more closely on the chart.
What is Affymax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Affymax stocks are traded under the ticker AFFY.
Is Affymax stock price growing?▼
AFFY stock has risen by +0% compared to the previous week, the month change is a -9.09% fall, over the last year Affymax has showed a -58.33% decrease.
What were Affymax earnings last quarter?▼
AFFY earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Affymax revenue for the last year?▼
Affymax revenue for the last year amounts to 1.37M USD.
What is Affymax net income for the last year?▼
AFFY net income for the last year is -14.42M USD.
Does Affymax pay dividends?▼
Yes, AFFY dividends are paid en. The last dividend per share was 0.05 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Affymax have?▼
As of June 16, 2026, the company has 2 employees.
In which sector is Affymax located?▼
Affymax operates in the Health & Wellness sector.
When did Affymax complete a stock split?▼
Affymax has not had any recent stock splits.
Where is Affymax headquartered?▼
Affymax is headquartered in New York, United States.